Philip Goelet, Ph.D. | Chairman
Philip has extensive experience as a scientist, entrepreneur and investor. He has co-founded and invested in a number of biotechnology companies including Molecular Tool, Inc. (acquired by Orchid Biosciences), RiboTargets, Plc. (merged with Vernalis), Population Genetic Technologies, Arginetix (acquired by AstraZeneca), ZuvaChem and AgriMetis. In parallel he co-founded Acidophil LLC, an innovation partnership, with Nobel Laureate Sydney Brenner, and Red Abbey Venture Partners, a health care private equity fund. His interest in utilizing molecular biology and biochemistry to assist agriculture began with the sequencing of tobacco mosaic virus in 1982.
John Atkin, Ph.D. | Board Member
John currently serves a number of board and advisory roles and is a board member of the Syngenta Foundation for Sustainable Agriculture, a non-profit organization. Previously, he was the Chief Operating Officer for Syngenta from the foundation of the company in 2000 until 2014. He had earlier roles as Chief Executive Officer for Novartis Crop Protection following a number of commercial and R&D leadership positions in Sandoz, FMC and Rhône-Poulenc.
Philip Austin | Board Member
Philip is a founding partner at Anterra Capital, a leading specialist investment fund in the food & agricultural sector. He currently heads up Anterra’s US office, dedicating most of his investment efforts to furthering life science companies in the food & agricultural sector. Prior to co-founding Anterra, Philip worked in the principal investment team of Rabobank International (Amsterdam, Netherlands), supporting this global leader in agricultural banking to make investments in groundbreaking, early stage technology companies. Philip started his investment career with Atlas Venture in London, United Kingdom. Prior to this, he was a strategy consultant with McKinsey & Company's London and Washington, D.C. offices. Philip holds a dual degree in Pharmaceutical Chemistry and Chemical Engineering.
Roger Kemble, Ph.D. | Board Member
Roger served a number of leadership roles for Syngenta including President of Syngenta Biotechnology Inc., Global Head of Crop Genetics Research and Global Head of Technology Strategy & Integration from 2002 retiring in 2012. Prior to that, he held management positions at Pioneer Hi-Bred International, a DuPont company (1991-2002), Allelix Crop Technologies and Allelix Inc. (1983-1991). In parallel to his industrial career he had an academic career as a professor at University of Toronto with an adjunct professorship at University of Waterloo, following work as an Assistant Professor at Kansas State University. Post-doctoral research was performed at University of Florida and the Plant Breeding Institute, Cambridge, UK following a Ph.D. from King's College, London.
Derek Norman, Ph.D. | Board Member
Derek is the Head of Corporate Venture Capital for Syngenta Ventures, the corporate venture capital group of Syngenta. Syngenta is one of the world’s largest agricultural companies focused on increasing agricultural productivity. Derek joined Syngenta Ventures as one of the founding members, where he is responsible for a number of investments across the agricultural value chain. Derek holds a B.S. degree in chemistry, with Honors, from Stanford University, a Ph.D. degree in Chemistry and Chemical Biology from Harvard University, and he is a member of Phi Beta Kappa.
Steven Tuttle | President & CEO
Steven comes with more than 25 years of global agricultural business experience and expertise. His experience includes building, running, developing and leading global businesses. Specifically, within the Agricultural Segment he has held several sales, marketing and commercial management roles. He has been global business director for the insecticides and fungicide portfolios within Dow Agro Sciences. In addition, responsibility as global business director for the Bioscience platform, Ventures & Business development and Alternative Energy Business (AEB) within The Dow Chemical Company. Steve served as President and Chief Executive Officer of Dow Kokam LLC. He has traveled globally since 1994 and lived for 6 years in Tokyo Japan. Steve will be accountable for building out the team that will shape and accelerate AgriMetis’s approach to develop and deliver new innovated molecules to the global agricultural market. He earned a bachelor's degree in Agricultural Engineering from The Ohio State University.
Matt Zuga, MBA | Board Member
Matt is a co-founder of HighCape Partners, a growth equity firm that invests in companies commercializing high-margin life sciences products. Prior to that, he was a Managing Director of Syngenta Ventures. He was a founder and managing member of Red Abbey Venture Partners (RAVP), where he is currently a member of the Investment Committee. He is currently the Co-Chairman of the Board of Directors of Alba Therapeutics, Inc. He was a member of the Board of Directors of Arginetix, Inc. and a Board observer at Advanced BioHealing, Aegerion Pharmaceutical, Sirtris Pharmaceuticals and Stromedix, Inc. Prior to RAVP, Matt was Head of Life Sciences investment banking at Legg Mason. Matt received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from The Ohio State University.
AgriMetis Board Observers
Sanne de Jongh | Board Observer
Sanne is an Analyst at Anterra Capital. She began her investing career at MS Ventures, the venture capital arm of Merck Serono, where she focused on early stage investments in the pharmaceutical industry. During this time, she worked on deal sourcing and portfolio management. Sanne holds a Masters in Biochemical Engineering from the Delft University of Technology. She has also studied at Leiden University and has conducted research in the fields of neurology, bionanoscience and environmental biotechnology.
Andrew Senesi, Ph.D. | Board Observer
Andrew Senesi is an Associate with the Beyond Healthcare Team within the TechAtlas division of RA Capital Management. Andrew's primary responsibility at RA Capital is to identify and assess orthogonal technologies that intersect with the healthcare industry. Andrew holds a Ph.D. in Chemistry from Northwestern University, where he focused on the development of DNA scaffold-based nanoparticle superlattices with novel emergent properties. His postdoctoral work at Argonne National Laboratories involved characterization of nanomaterials using X-ray scattering technologies. Andrew worked previously as an associate at the Chicago Innovation Exchange, a University of Chicago-focused incubator with an associated VC fund.